Search
for
Sort by
Research 571–600 of 577
- Real-world evidence in alopecia areata treatment: A narrative review
- Unlocking the Potential of Rosemary in Alopecia: A Narrative Review of Evidence on Mechanism, Applications and Challenges
- Table_1_Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea.xlsx
- Androgenetic alopecia – Update 2022
- A cross-sectional study of clinical, dermoscopic, histopathological, and molecular patterns of scalp melanoma in patients with or without androgenetic alopecia
- Update From Dermatology Nurses’ Association Convention 2025
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway
- Molecular crosstalk between lncRNA H19, miR-29a, and JAK2/STAT3 signaling in alopecia areata: a preliminary study
- Interleukin-6 Null Mice Paradoxically Display Increased STAT3 Activity and Wound-Induced Hair Neogenesis
- Under Development JAK Inhibitors for Dermatologic Diseases
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- Myeloproliferative disorder associated with alopecia universalis
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- INVESTIGATING THE MECHANISMS UNDERLYING THE PATHOGENESIS OF ALOPECIA AREATA
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- Pharmacological Treatment of Alopecia
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Anticancer Effects of Cepharanthine: an Updated Minireview
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies